Cimzia (certolizumab pegol) solution for injection (pre-filled syringes) — Vetter Pharma-Fertigung GmbH & Co. KG (Germany) Rheumatoid arthritis treatment Targeted cancer therapy. Delivery of medications from Europe, guaranteed storage conditions, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Rheumatoid Arthritis

Treatment of moderate to severely active rheumatoid arthritis in adults (18 years and older):

• in combination with methotrexate in cases of insufficient response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate;
• as monotherapy in cases of intolerance to or inappropriateness of further treatment with methotrexate.

Cimzia®, when used in combination with methotrexate, has been shown to reduce the progression of joint damage assessed by radiography and improve physical function.

Disease Crohn's disease

Treatment of Crohn's disease with moderate to severe disease activity in adults who have failed DMARD therapy.

Axial spondyloarthritis

Cimzia^® is indicated for the treatment of severe active axial spondyloarthritis in adults, including:

• severe active ankylosing spondylitis in adults who have had an inadequate response to, or are intolerant of, nonsteroidal anti-inflammatory drugs (NSAIDs);
• severe active axial spondyloarthritis without radiographic evidence of AS, but with objective evidence of inflammation, manifested by an increase in CRP concentrations and/or with corresponding changes in magnetic resonance imaging (MRI), in whom an inadequate response to, or intolerance to, NSAIDs is present. intolerance.

Psoriatic Arthritis

Treatment of active psoriatic arthritis in adults:

• in combination with methotrexate in case of insufficient response to DMARD therapy;
• as monotherapy in case of intolerance or inappropriateness of further treatment with methotrexate.